Amicus Therapeutics Inc (FOLD) saw a significant price increase of 30.17% in pre-market trading, reaching a 52-week high. This surge reflects a positive sentiment in the biotech sector, which has been buoyed by recent developments in drug approvals and strategic collaborations.
The stock's rise is attributed to the overall strength in the biotech industry, which has shown resilience amid challenges. The sector is experiencing a wave of mergers and acquisitions, with companies focusing on innovative treatments and strategic partnerships to enhance their portfolios. This context suggests that investors are shifting their focus towards biotech stocks, contributing to Amicus Therapeutics' strong performance.
As the biotech sector continues to thrive, driven by new drug approvals and a favorable market environment, Amicus Therapeutics is well-positioned to capitalize on these trends. The company's innovative pipeline and strategic initiatives may further enhance its growth potential in the coming months.
Wall Street analysts forecast FOLD stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for FOLD is 14.25 USD with a low forecast of 11.00 USD and a high forecast of 19.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
Wall Street analysts forecast FOLD stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for FOLD is 14.25 USD with a low forecast of 11.00 USD and a high forecast of 19.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
7 Hold
0 Sell
Moderate Buy
Current: 14.270
Low
11.00
Averages
14.25
High
19.00
Current: 14.270
Low
11.00
Averages
14.25
High
19.00
Jefferies
Buy
to
Hold
downgrade
$16
2026-01-22
Reason
Jefferies
Price Target
$16
AI Analysis
2026-01-22
downgrade
Buy
to
Hold
Reason
Jefferies downgraded Amicus to Hold from Buy with a price target of $14.50, down from $16. Proxy documents show the company did receive extensive pharma takeover interest beyond BioMarin, the analyst tells investors in a research note. As such, Jefferies does not expect additional takeover bids for Amicus.
Citi
Samantha Semenkow
Buy
initiated
$17
2025-12-17
Reason
Citi
Samantha Semenkow
Price Target
$17
2025-12-17
initiated
Buy
Reason
Citi analyst Samantha Semenkow initiated coverage of Amicus with a Buy rating and $17 price target. The company is focused on commercializing rare disease therapies, the analyst tells investors in a research note. The firm believes Galafold and PomOp are positioned for combined sales of over $1B in 2028.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for FOLD
Unlock Now
JPMorgan
NULL -> Overweight
maintain
$18 -> $19
2025-11-06
Reason
JPMorgan
Price Target
$18 -> $19
2025-11-06
maintain
NULL -> Overweight
Reason
JPMorgan raised the firm's price target on Amicus to $19 from $18 and keeps an Overweight rating on the shares. The firm updated the company's model.
Goldman Sachs
Neutral
maintain
$9 -> $11
2025-11-05
Reason
Goldman Sachs
Price Target
$9 -> $11
2025-11-05
maintain
Neutral
Reason
Goldman Sachs raised the firm's price target on Amicus to $11 from $9 and keeps a Neutral rating on the shares. Amicus reported Q3 revenue in line with estimates, and Goldman Sachs is encouraged by continued commercial execution per positive GAAP net income in Q3, which should be sustained from here, and management's confidence in achieving FY25 consensus revenue, the analyst tells investors in a research note.
About FOLD
Amicus Therapeutics, Inc. is a global biotechnology company focused on discovering, developing and delivering medicines for people living with rare diseases. Its two marketed therapies are Galafold, the first oral monotherapy for people living with Fabry disease who have amenable genetic variants, and Pombiliti + Opfolda, a two-component treatment for adults living with late-onset Pompe disease. As an orally miglustat monotherapy, Galafold is designed to bind to and stabilize an endogenous alpha-galactosidase A enzyme in those patients with genetic variants identified as amenable in a Good Laboratory Practice cell-based amenability assay. Pombiliti + Opfolda consists of an engineered rhGAA enzyme, cipaglucosidase alfa-atga, with an optimized carbohydrate structure to enhance cellular uptake, administered intravenously in combination with orally administered miglustat. In addition, clinical studies are ongoing in pediatric patients for both the LOPD and IOPD populations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
